These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 17785545)

  • 1. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
    Kelland L
    Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
    Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
    Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
    Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
    Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomeres as targets for anticancer therapies.
    Folini M; Venturini L; Cimino-Reale G; Zaffaroni N
    Expert Opin Ther Targets; 2011 May; 15(5):579-93. PubMed ID: 21288186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
    Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E; Faivre S; Dieras V; Von Hoff D
    Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ageing and cancer: the telomere and telomerase connection.
    Shay JW; Wright WE
    Novartis Found Symp; 2001; 235():116-25; discussion 125-9, 146-9. PubMed ID: 11280022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [siRNA targeting telomerase--effective tool in anti-cancer therapy?].
    Rubiś B; Półrolniczak A; Rybczyńska M
    Postepy Biochem; 2008; 54(4):384-92. PubMed ID: 19248585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance.
    Cerone MA; Londoño-Vallejo JA; Autexier C
    Oncogene; 2006 Nov; 25(56):7411-20. PubMed ID: 16767163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of telomerase activity and telomere length.
    Wu KD; Moore MA
    Methods Mol Med; 2005; 113():207-23. PubMed ID: 15968105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of telomerase activity and telomere length to chemosensitivity.
    Kiyozuka Y
    Methods Mol Med; 2005; 111():97-108. PubMed ID: 15911975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
    Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
    Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The many faces of telomerase: emerging extratelomeric effects.
    Bollmann FM
    Bioessays; 2008 Aug; 30(8):728-32. PubMed ID: 18623070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G-quadruplex stabilizer 3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells.
    Huang FC; Chang CC; Lou PJ; Kuo IC; Chien CW; Chen CT; Shieh FY; Chang TC; Lin JJ
    Mol Cancer Res; 2008 Jun; 6(6):955-64. PubMed ID: 18515756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of telomeres and telomerase in the pathogenesis of human cancer.
    Hahn WC
    J Clin Oncol; 2003 May; 21(10):2034-43. PubMed ID: 12743159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.